Mon. Jul 4th, 2022
Pompe Disease Market

DelveInsight’s “Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Interstitial Lung Disease market trends in the seven major markets (7MM) (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The report also covers provides insights into the emerging drugs, current treatment practices, market share of the individual therapies, market drivers, barriers, unmet medical needs, current and forecasted market size from 2019 to 2032 segmented by 7MM. 

Interstitial Lung Disease Disease Overview

According to the American Lung Association, ILD is a general term for a large group of disorders that cause scarring or fibrosis of the lungs. Fibrosis or scarring can be part of the healing response to injury, but fibrosis as a disease process occurs when restoration to normal tissue does not occur. The scarring causes stiffness in the lungs, which makes it difficult to breathe. The disease is characterized by the presence of inflammation and altered-lung interstitium.

There are more than 200 different conditions included among the total number of ILDs. In most cases, the causes are unidentified. In some cases, it may be caused by contact with hazardous chemicals, irritants, certain medications, pathogenic infections (with bacteria, viruses, and fungi), and medical treatment. 

Interstitial Lung Disease Market Key Facts

  • According to the research study by Black et al., the overall incidence of ILDs in the US was slightly more common in males (31.5 per 100,000/year) than females (26.1 per 100,000/year) for the study period of 1988–1990. The most common incident diagnosed among both sexes were pulmonary fibrosis and idiopathic pulmonary fibrosis, together accounting for 46.2% of all ILD diagnoses in males and 44.2% in females.
  • In a population-based study of Northern Europe, the reported overall incidence rate of ILDs was 31 per 100,000 for 2001 to 2005. The study observed a 33% increase in the incidence from 1995 to 2000. The increased incidence was observed in all age groups and both genders. (Kornum et al., 2008).

Interstitial Lung Disease Market

The Interstitial Lung Disease market is expected to increase during the forecast period owing to the launch of upcoming therapies.

The market outlook section of the report helps to understand the historic, current, and forecasted Interstitial Lung Disease market size by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology. 

The report gives a thorough detail of key trends, ongoing developments, and growth opportunities of each marketed and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders in the domain. 

Get the PDF Sample of the Report @

Interstitial Lung Disease Epidemiology

The epidemiology section covers insights into the historical and current Interstitial Lung Disease patient pool and forecasted trends for every seven major markets from 2019 to 2032. 

It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Discover more about the epidemiological segmentation @

Interstitial Lung Disease Epidemiology Subtype Segmentation

  • Total Incidence 
  • Gender-specific cases
  • Diagnosed and Treatable cases 
  • Subtype-specific cases (Unknown etiology, exogenous etiology, and variable etiology)

Interstitial Lung Disease Drugs Uptake and Key Market Players

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Interstitial Lung Disease market or expected to get launched in the market during the study period. The analysis covers the drug uptake; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the Interstitial Lung Disease Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent development such as collaborations, acquisitions, and mergers, licensing patent details, and other information.

Interstitial Lung Disease Therapeutics Analysis

Some of the key companies in the Interstitial Lung Disease Market include:

  • Roche
  • aTyr Pharma
  • Galapagos 
  • OncoArendi Pharmaceuticals

And others 

Interstitial Lung Disease Therapies covered in the report include:

  • Pirfenidone
  • ATYR1923
  • Abatacept
  • OATD-01

And others

Get More Detailed Insights into the Emerging Therapies & Key Companies:-

Table of Content

  1. Key Insights
  2. Executive Summary 
  3. Interstitial Lung Disease Competitive Intelligence Analysis
  4. Interstitial Lung Disease Market Overview at a Glance
  5. Interstitial Lung Disease Disease Background and Overview
  6. Interstitial Lung Disease Patient Journey
  7. Interstitial Lung Disease Epidemiology and Patient Population
  8. Interstitial Lung Disease Treatment Algorithm, Current Treatment, and Medical Practices
  9. Interstitial Lung Disease Unmet Needs
  10. Key Endpoints of Interstitial Lung Disease Treatment
  11. Interstitial Lung Disease Marketed Products
  12. Interstitial Lung Disease Emerging Therapies
  13. Interstitial Lung Disease Seven Major Market Analysis
  14. Attribute Analysis
  15. Interstitial Lung Disease Market Outlook (7 major markets)
  16. Interstitial Lung Disease Access and Reimbursement Overview
  17. KOL Views on the Interstitial Lung Disease Market.
  18. Interstitial Lung Disease Market Drivers
  19. Interstitial Lung Disease Market Barriers
  20. Appendix
  21. DelveInsight Capabilities
  22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:-

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. 

Contact Info:
Shruti Thakur
Assistant Manager, Marketing & IB
Phone No: +91-9650213330
Email: [email protected]
Connect With Us: LinkedIn | Facebook | Twitter
For Latest Update: Healthcare Blog
Request for Sample Copy of the Report at:


Latest Reports By DelveInsight:

Other Trending Healthcare Reports by DelveInsight


By krehani

Leave a Reply

Your email address will not be published. Required fields are marked *